SCHEMBL15550994

SCHEMBL15550994

CCc1c(C(N)=O)cccc1-c1nc2ccccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.58
KDM4E B2RXH2 4/20 0.58
MAPT P10636 2/20 0.55
HTT P42858 2/20 0.55
PARP1 P09874 7/20 0.52
SMN1; SMN2 Q16637 5/20 0.51
HPGD P15428 3/20 0.50
NPC1 O15118 4/20 0.49
ALDH1A1 P00352 4/20 0.49
NPSR1 Q6W5P4 2/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
F7 P08709 1/20 0.47
PKM P14618 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30412663 0.84 RAB9A (0.75) RAB9AKDM4EMAPTHTTPARP1
SCHEMBL3698974 0.84 RAB9A (0.75) RAB9AKDM4EMAPTHTTPARP1
SCHEMBL30335387 0.83 SMN1; SMN2 (0.64) RAB9AKDM4EMAPTHTTPARP1
SCHEMBL28978359 0.83 SMN1; SMN2 (0.64) RAB9AKDM4EMAPTHTTPARP1
SCHEMBL17372933 0.82 RAB9A (0.63) RAB9AKDM4EMAPTHTTPARP1
SCHEMBL15550990 0.81 PARP1 (0.50) RAB9AKDM4EMAPTHTTPARP1
SCHEMBL15550309 0.81 CHEK1 (0.46) RAB9AKDM4EMAPTHTTSMN1; SMN2
SCHEMBL15550758 0.80 PARP1 (0.60) RAB9AKDM4EMAPTHTTPARP1
SCHEMBL21947288 0.78 KDM4E (0.69) RAB9AKDM4EMAPTHTTSMN1; SMN2
SCHEMBL3662654 0.76 KDM4E (0.59) RAB9AKDM4EMAPTPARP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA RAB9A 1951/4885KDM4E 3916/4885MAPT 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.